Coronavirus Outbreak: Leaked results of a clinical trial hints Gliead's Remdesivir could be possible COVID-19 cure

During the trial, 113 patients were treated with the drug, most were discharged from the hospital in under a week, and only two died.

The New York Times April 24, 2020 08:05:43 IST
Coronavirus Outbreak: Leaked results of a clinical trial hints Gliead's Remdesivir could be possible COVID-19 cure

Diana Brainard is nowhere near close to celebrating.

Brainard is the head of antiviral clinical research at Gilead Sciences, the Bay Area biotech giant whose drug portfolio includes the antiviral medicine remdesivir. On Thursday, Stat, the superb medical-news website, reported some of the leaked results of a pair of Phase 3 clinical trials of the drug at the University of Chicago. Of 113 patients with severe cases of COVID-19 who were treated with daily infusions of remdesivir, most were discharged from the hospital in under a week, and only two died.

That sounds like fantastically good news, but Brainard has caveats and cautions. The Chicago story, she told me in a phone interview this week, is still anecdotal. The trial did not include a control group. Hard data, once it comes, can be hard to interpret. “We have to assess whether the drug is working without having a clear picture of what is typical with this disease,” she says.

 <span class=Coronavirus Outbreak Leaked results of a clinical trial hints Glieads Remdesivir could be possible COVID19 cure" width="1280" height="720" />

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. Image credit: Gilead Sciences via AP

But whether remdesivir turns out to be effective or not — and it’s always wise to curb one’s enthusiasm about supposed miracle cures — the remarkable thing is that it’s available at all. It began life in 2009 as a potential treatment for hepatitis C but didn’t work as hoped. It got a second chance during an Ebola outbreak in Congo. It showed limited effects but proved safe to use on people.

Also Read: Is plasma therapy the miracle cure the world has been waiting for? 

Lab tests, however, suggested it might have potent effects against coronavirus es such as those that cause SARS and MERS. As it became clear that COVID-19 was also caused by a coronavirus , remdesivir was one of the few potentially helpful drugs ready to be in clinical trials. Gilead began distributing it on a compassionate-use basis on 25 January.

“By March we were getting hundreds of requests a day,” Brainard says. “We needed to pivot to a different kind of system — expanded access. Instead of providing the drug to each patient individually, you provide it to individual physicians and they administer it as they see fit.”

It was around that time that I first started paying attention to this story, thanks to a reader with a severely sick young relative who couldn’t obtain remdesivir. The relative has since come off a ventilator and is staging a painful recovery, but his family felt Gilead had been capricious in the ways it made the drug available.

Brainard is aware of the agony such families face: “The majority of us are infectious-disease physicians, and we know what it’s like to treat a critically ill patient deteriorating before our eyes.” Especially now, Gilead and its biotech peers have to walk a fine line between offering hope and inflating expectations and moving with all possible speed as well as utmost caution. A manufacturing glitch can become a corporate disaster. A small delay can mean tragedy for an untold number of families.

 <span class=Coronavirus Outbreak Leaked results of a clinical trial hints Glieads Remdesivir could be possible COVID19 cure" width="1280" height="720" />

Lab tests suggested Remdesivir might be effective against coronavirus es and since COVID-19 is part of the family, it was one of the few potentially helpful drugs ready to be in clinical trials.

“Facts and science are hard masters, and we can’t build the factory until we know the medicine,” Kevin Sharer, a former CEO of biotech giant Amgen, told me Friday. “Ultimately there’s an element of chance we cannot control.”

The next step is to inspect the data from Chicago and other concurrent studies of remdesivir now involving 6,000 participants with severe symptoms. If the results hold up — the if always has to be stressed — the Food and Drug Administration and other regulatory agencies would have to provide approval. That could take a full year, barring an expedited process. Then production of the drug would need to ramp up quickly, no small thing as remdesivir requires complex manufacturing techniques.

Given the stakes involved, it seems perverse not to root for Gilead’s success. Just as there are no atheists in foxholes, there should be no big-pharma haters in pandemics. Last year, Elizabeth Warren wrote that “giant drug companies only care about one thing: raking in profits on the backs of patients.” I wonder if the Massachusetts senator would have the nerve to say that to Brainard and every other private-sector scientist labouring to find cures under the intense strain of this global emergency.

It’s also worth asking what this story says about the notion that the pandemic somehow proves Bernie Sanders right. “Medicare For All,” achieved through wrenching changes at the ruinous expense, might provide “coverage” for every American, including the millions of newly unemployed.

Also read: coronavirus test centres near you? List of private, government testing sites in all States, Union Territories in India"}" data-sheets-userformat="{"2":513,"3":{"1":0},"12":0}">Looking for coronavirus test centres near you? List of private, government testing sites in all States, Union Territories in India

But that’s of little help without effective diagnostic tests, therapies and vaccines, which typically emerge from profit-seeking companies operating in fiercely competitive and well-regulated marketplaces. Whatever the fate of remdesivir or any other drug, one lesson from this pandemic is how dependent we are for our survival on an innovative and robust pharmaceutical industry. Maybe we should do more as a country to cultivate it than tear it down.

In the meantime, we’re left to wait. “Nobody is drinking any Champagne, it’s premature to celebrate, nobody wants to jinx anything,” Brainard says of the mood among her colleagues. Scepticism is always a sound scientific attitude. For the rest of us: Cross fingers.

Bret Stephens c.2020 The New York Times Company

Updated Date:

also read

Germany 'urgently preparing' mission of support to help India battle COVID-19, says Chancellor Angela Merkel
India

Germany 'urgently preparing' mission of support to help India battle COVID-19, says Chancellor Angela Merkel

While Merkel did not offer details, Der Spiegel weekly on Saturday said Germany's armed forces had received a request to help organise oxygen supplies

One in four people experience mild, brief side-effects of COVID-19 vaccines: Lancet study
science

One in four people experience mild, brief side-effects of COVID-19 vaccines: Lancet study

People with prior known COVID-19 infection were also more likely to experience local side effects.

Wimbledon organisers announce that rest day in middle of tournament will be scrapped from 2022
Sports

Wimbledon organisers announce that rest day in middle of tournament will be scrapped from 2022

Wimbledon is the only Grand Slam that has a day off during the fortnight but this provides scheduling challenges, particularly when there is bad weather in the first week.